Vališ Martin, Pavelek Zbyšek, Novotný Michal, Klímová Blanka, Šarláková Jana, Halúsková Simona, Peterka Marek, Štětkárová Ivana, Štourač Pavel, Mareš Jan, Hradílek Pavel, Ampapa Radek, Vachová Marta, Recmanová Eva, Meluzínová Eva
Department of Neurology, University Hospital Hradec Kralove, Hradec Kralove, Czechia.
Department of Neurology, Faculty of Medicine, University Hospital Plzen, Charles University, Plzen, Czechia.
Front Neurol. 2022 Apr 18;13:851426. doi: 10.3389/fneur.2022.851426. eCollection 2022.
Multiple sclerosis can also affect children. Approximately 3-10% of patients develop multiple sclerosis before the age of 16.
The aim of this analysis is to describe the characteristics of pediatric patients with multiple sclerosis who started their treatment with disease-modifying drugs in 2013-2020, with data obtained from the Czech National Registry of patients with multiple sclerosis.
A method of retrospective analysis conducted with 134 pediatric patients with multiple sclerosis was used.
The findings reveal that the mean age at the date of the introduction of the first disease-modifying drugs treatment is 15.89 years, and gender does not play any role. In addition, moderate (51.6%) and mild (45.2%) relapses are predominant in these young patients. Seventy five percent of patients will not experience a confirmed progression of the expanded disability status scale within 54.7 months from starting the treatment. Furthermore, the results confirm that the first-choice treatment is interferon beta-a and glatiramer acetate, which is common for adult patients. However, some factors, such as a low efficacy or a lack of tolerance may impact on treatment discontinuation in children.
More research should be performed on novel disease-modifying drugs for this target group.
多发性硬化症也会影响儿童。约3%-10%的患者在16岁之前患上多发性硬化症。
本分析旨在描述2013年至2020年开始使用疾病修正药物治疗的小儿多发性硬化症患者的特征，数据来自捷克国家多发性硬化症患者登记处。
采用对134例小儿多发性硬化症患者进行回顾性分析的方法。
研究结果显示，首次使用疾病修正药物治疗时的平均年龄为15.89岁，性别不产生任何影响。此外，这些年轻患者中中度（51.6%）和轻度（45.2%）复发占主导。75%的患者在开始治疗后的54.7个月内不会出现经确认的扩展残疾状态量表进展情况。此外，结果证实首选治疗药物为β-干扰素和醋酸格拉替雷，这在成年患者中也很常见。然而，一些因素，如疗效低或耐受性差，可能会影响儿童停药。
应针对这一目标群体对新型疾病修正药物开展更多研究。
